Announcement of New CEO
Tokyo, Japan, July 1, 2020 - LUCA Science Inc. (Head office: Chuo-ku, Tokyo) the leading biotechnology company focused on the development of innovative mitochondria therapies to address highly unmet medical needs announced today that Dr. Rick C. Tsai will become the new Chief Executive Officer (CEO) of the company, effective July 1, 2020. Dr. Tsai succeeds Dr. Masashi Suganuma, who will continue in his capacity as Chairman and Chief Scientific Officer for LUCA Science.
LUCA Science Inc. have announced the following changes in officers effective July 1, 2020.
| New Position | Name | Former Position |
|---|---|---|
| President and Chief Executive Officer | Rick C. Tsai DMD, MD | (Newly-appointed) |
| Chairman and Chief Scientific Officer | Masashi Suganuma MD, Ph.D | President and Chief Executive Officer |
[Executive Profile]
CEO Dr. Rick C. Tsai
Rick joined LUCA Science as Chief Executive Officer on July 1st 2020. Before joining LUCA Science, he served as Executive Officer and head of Medical Affairs department for MSD K.K., a subsidiary of Merck & Co. Inc. During his tenure at MSD, he has also led the Regulatory Affairs and Clinical Development team in multiple therapeutic areas in Japan. In addition to MSD, Rick has worked as a Medical Director for Allergan in Japan China, Taiwan and Hong Kong. Prior to joining pharmaceutical industry Rick was an Oral Maxillofacial surgeon and research scientist at Columbia University.
Rick holds a DMD (Doctor of Dental Medicine) degree from Harvard University and MD (Doctor of Medicine) from Columbia University.